



## Olema Oncology to Participate in Upcoming Investor Conferences in May

May 1, 2024

SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema", "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will participate in the following upcoming investor conferences:

### **BofA Securities Health Care Conference 2024**

Date: Tuesday, May 14, 2024, at 4:35 p.m. PT

Location: Encore Hotel in Las Vegas, NV

Format: Presentation

### **H.C. Wainwright 2<sup>nd</sup> Annual BioConnect Investor Conference**

Date: Monday, May 20, 2024, at 4:00 p.m. ET

Location: NASDAQ Headquarters in New York, NY

Format: Fireside Chat

### **UBS Spring Biotech Symposium**

Date: Tuesday, May 21, 2024

Location: New York, NY

Format: One-on-one Meetings

### **TD Cowen 5th Annual Oncology Innovation Summit**

Date: Tuesday, May 28, 2024, at 10:00 a.m. ET

Location: Virtual

Format: Fireside Chat

Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema's investor relations website at [ir.olema.com](http://ir.olema.com). The webcasts will be archived for at least 30 days.

### **About Olema Oncology**

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at [www.olema.com](http://www.olema.com).

#### **Contact:**

Geoffrey Mogilner, Vice President, Investor Relations and Communications

[ir@olema.com](mailto:ir@olema.com)